As advised via PHARMAC Tender Results of 30 April 2019 there is to be a change in the listing and future sole supply of Sodium Chloride Inj 0.9% 5 ml, 10 ml & 20 ml.

New listing from 1 July 2019

Sodium Chloride Inj 0.9% 5 ml 20         Fresenius Kabi             Pharmacode 2565749                    Schedule price $2.80

Sodium Chloride Inj 0.9% 10 ml 50      Fresenius Kabi              Pharmacode 2565757                    Schedule price $5.40

Sodium Chloride Inj 0.9% 20 ml 20      Fresenius Kabi              Pharmacode 2565730                    Schedule price $5.00

Incumbent brands

Sodium Chloride Inj 0.9% 5 ml 50         Multichem                      Pharmacode 2320541             Schedule price $7.00

Sodium Chloride Inj 0.9% 5 ml 50         InterPharma                   Pharmacode 2471094            Schedule price $7.00

Sodium Chloride Inj 0.9% 10 ml            50       Pfizer                     Pharmacode 691968             Schedule price $6.63

Sodium Chloride Inj 0.9% 20 ml 20      Multichem                       Pharmacode 2249200             Schedule price $5.00

Sodium Chloride Inj 0.9% 20 ml 30      InterPharma                    Pharmacode 2471116             Schedule price $7.50

HSS (Hospital Supply Status) & CSS (Community Supply Status) commences 1 December 2019.

Brand switch fee for Community Pharmacy has not been advised.

As of the date of this notification ProPharma / PWR cannot accept Sodium Chloride Inj 0.9% Pfizer, Multichem or InterPharma  for credit under any circumstances.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.

You MUST manage your stock to avoid being caught with stock at the time sole supply commences 1 December 2019. Failure to do so may prove very costly.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply 1 December 2019 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author

Close